Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
ACET Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Adicet Bio, Inc.NASDAQ: ACET
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 11.4% from a year ago
Total assets stood at $169.38M at the end of Q1 FY2026, down 11.4% from a year earlier and down 11.9% from the prior quarter. Over 3 fiscal years it compounded at -16.5% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -11.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 192.36M USD
- Year-over-year change
- -12.7%
- 4-year CAGR
- -13.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 192.36M | -12.7% |
| FY2024 | 2024-12-31 | 220.22M | +6.2% |
| FY2023 | 2023-12-31 | 207.3M | -37.3% |
| FY2022 | 2022-12-31 | 330.69M | -2.4% |
| FY2021 | 2021-12-31 | 338.94M | — |
Total Assets vs competitors
How ACET compares with its peers on the latest reported figures
- ACET's Mar 2026 total assets of $169.38M is the 3rd highest of the 8 companies compared; the peer median is $78.26M.
- Its year-over-year change of -11.4% is the 4th highest of 8, against a peer median of -12.3%.
- Over three fiscal years its annual growth of -16.5% compares with a peer median of -19.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $201.99M | -39.3% | +4.7% | |
| Mar 2026 | $189.74M | +824.9% | -42.7% | |
| Mar 2026 | $169.38M | -11.4% | -16.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $107.83M | -38.9% | -10.5% |
| Dec 2025 | $78.26M | -12.3% | -19.9% | |
| Jun 2026 | $24.16M | -73.9% | -24.3% | |
| Mar 2026 | $18.74M | +61.2% | -1.8% | |
| Mar 2026 | $11.9M | +56.8% | -20.5% | |
| Peer median (excluding ACET) | $78.26M | -12.3% | -19.9% | |
Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 277.54M | 257.66M | 159.71M | 56.5M | 38.92M |
| Short-term Investments | 0 | 0 | 0 | 119.81M | 119.61M |
| Net Receivables | 214K | 435K | 0 | 0 | 342K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2K | 336K | 457K | 474K | 320K |
| Total Current Assets | 282.44M | 261.04M | 162.27M | 180.14M | 160.93M |
| Property, Plant & Equipment (Net) | 35M | 48.98M | 44.2M | 36.75M | 28.48M |
| Goodwill | 19.46M | 19.46M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.87M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.04M | 1.21M | 822K | 3.33M | 76K |
| Total Non-current Assets | 56.5M | 69.65M | 45.02M | 40.08M | 31.43M |
| Total Assets | 338.94M | 330.69M | 207.3M | 220.22M | 192.36M |
| Account Payables | 3.26M | 4.4M | 2.63M | 4.83M | 4.74M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.81M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.02M | 5.7M | 6.93M | 7.11M | 5.63M |
| Total Current Liabilities | 16.32M | 19.71M | 19.29M | 19.39M | 21.53M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 115K | 114K | 130K | 116K | 62K |
| Total Non-current Liabilities | 19.49M | 18.65M | 17.83M | 14.22M | 11.61M |
| Total Liabilities | 35.81M | 38.35M | 37.12M | 33.61M | 33.15M |
| Common Stock | 4K | 4K | 4K | 8K | 10K |
| Retained Earnings | (168.32M) | (238.11M) | (380.77M) | (497.89M) | (614.7M) |
| Accumulated OCI | 0 | 0 | 0 | 16K | 102K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 303.13M | 292.34M | 170.18M | 186.61M | 159.21M |
| Total Debt | 20.94M | 21.02M | 20.92M | 17.23M | 14.74M |
| Net Debt | (256.6M) | (236.63M) | (138.79M) | (39.26M) | (24.18M) |
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.